menu
    • menu

    Company profile for Eikon Therapeutics

    NEW Drugs in Dev: 7
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Eikon Therapeutics is a biopharmaceutical company pioneering the integration of advanced engineering and high-resolution microscopy to observe protein dynamics in living cells. This innovative approach accelerates the discovery of novel treatments for life-threatening diseases. Founded in 2019 and headquartered in Hayward, California, Eikon's multidisciplinary team is dedicated to transforming drug discovery and development. ...
    Eikon Therapeutics is a biopharmaceutical company pioneering the integration of advanced engineering and high-resolution microscopy to observe protein dynamics in living cells. This innovative approach accelerates the discovery of novel treatments for life-threatening diseases. Founded in 2019 and headquartered in Hayward, California, Eikon's multidisciplinary team is dedicated to transforming drug discovery and development.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Eikon TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3929 Point Eden Way, Hayward, CA 94545
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.eikontx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    euroPLX 90 Lisbon

    Not Confirmed

    envelop Contact Supplier

    euroPLX 90 Lisbon

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Eikon Upsized $381M Listing Marks Largest Biotech IPO Since 2024
    Eikon Upsized $381M Listing Marks Largest Biotech IPO Since 2024

    05 Feb 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/eikons-upsized-381m-nasdaq-listing-marks-largest-biotech-ipo-2024

    FIERCE BIOTECH
    05 Feb 2026
    Share Share
    Eikon Therapeutics Prices Upsized IPO
    Eikon Therapeutics Prices Upsized IPO

    04 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3232603/0/en/Eikon-Therapeutics-Announces-Pricing-of-Upsized-Initial-Public-Offering.html

    GLOBENEWSWIRE
    04 Feb 2026
    Share Share
    Eikon, Veradermics Announce IPO Targets Amid Cautious Optimism
    Eikon, Veradermics Announce IPO Targets Amid Cautious Optimism

    29 Jan 2026

    // BIOSPACE

    https://www.biospace.com/business/veradermics-eikon-eye-public-market-debut-as-ipo-tap-opens

    BIOSPACE
    29 Jan 2026
    Share Share
    Eikon Sets $274M Goal For Upcoming Stock Market Debut
    Eikon Sets $274M Goal For Upcoming Stock Market Debut

    28 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/eikon-sets-274m-goal-upcoming-stock-market-debut

    FIERCE BIOTECH
    28 Jan 2026
    Share Share
    Veradermics, Eikon Eye Public Market Debut As IPO Tap Opens
    Veradermics, Eikon Eye Public Market Debut As IPO Tap Opens

    12 Jan 2026

    // BIOSPACE

    https://www.biospace.com/business/veradermics-eikon-eye-public-market-debut-as-ipo-tap-opens

    BIOSPACE
    12 Jan 2026
    Share Share
    Eikon Plans IPO To Bankroll Clutch Of Clinical Cancer Drugs
    Eikon Plans IPO To Bankroll Clutch Of Clinical Cancer Drugs

    12 Jan 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/eikon-next-line-ipo-funds-set-bankroll-clutch-clinical-cancer-drugs

    FIERCE BIOTECH
    12 Jan 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search